Release of the 2014/15 Invitation to Tender

Transcription

1 6 November 2014 Release of the 2014/15 Invitation to Tender The 2014/15 Invitation to Tender (2014/15 ITT) has been distributed today. Please note that the Electronic Portal will not be available until approximately five working days following the release of the 2014/15 ITT. If you have not previously registered your contact details PHARMAC to access the Electronic Portal, and you would like to participate in the 2014/15 ITT, please contact the Tender Analysts at If you have registered your address us, you will receive an link to the Electronic Portal once it has become available. If you don t receive this link by 17 November, we suggest that you check your spam filters (in case it has been caught by your filters) prior to contacting us. A complete copy of the 2014/15 ITT is also available on our website at the following link We will not be posting out any hard copies of the 2014/15 ITT. 1. Changes to the 2014/15 ITT product list Please note that the product list (Schedule Two) consulted on in August 2014 has changed. Some products have been added, removed or amended either as a result of: clinical advice received (i.e. from the Tender Medical Evaluation Subcommittee of PTAC and/or members of the Hospital Pharmaceuticals Subcommittee); and/or consultation responses received from suppliers, DHBs and/or medical groups; and/or a review of unresolved bids from previous tenders; and/or Alternative Commercial Proposals accepted by PHARMAC. The following items have been added to the 2014/15 ITT: Abacavir Sulphate Lamivudine Alteplase Aqueous Cream Aqueous Cream Artesunate Tab 600 mg lamivudine 300 mg Inj 2 mg Crm (100 g or less) Benzoyl Peroxide Gel 2.5% Benzoyl Peroxide Gel 5% Betamethasone Valerate Oint 0.1% Crm (greater than 100 g) Inj 60 mg Bisacodyl Bisacodyl Calcium folinate Carboplatin Carboplatin Carmustine gluconate Cidofovir Cisplatin Cisplatin Suppos 10 mg Suppos 5 mg Tab 15 mg Inj 10 mg per, 100 Inj 10 mg per, 5 Inj 100 mg Lotn 1% obstetric Inj 375 mg per 5 Inj 1 mg per, 100 Inj 1 mg per, 50 Page 1 of 9

2 Citalopram hydrobromide Clofazimine Clonazepam Clonazepam Cyclophosphamide Cyclophosphamide Cyclophosphamide Dipyridamole Dorzolamide Dorzolamide timolol maleate Doxorubicin Doxorubicin Enalapril Hydrochlorothiazide Epirubicin Glycerol Glycerol Glyceryl trinitrate Hyoscine Hydrobromide Idarubicin Idarubicin Ketamine Ketamine Latanoprost timolol Tab 20 mg Cap 50 mg Tab 2 mg Tab 500 mcg Inj 1 g Inj 2 g Tab 50 mg Tab long-acting 150 mg Eye drops 2% Eye drops 2% timolol maleate 0.5% Inj 10 mg Inj 100 mg Tab 20 mg hydrochlorothiazide 12.5 mg Inj 2 mg per, 5 Inj 50 mg per, 10 Inj 50 mg per, 100 Inj 50 mg per, 20 Inj 50 mg per, 50 Suppos 1.27 g Suppos 2.55 g Inj 5 mg per, 10 Oral liq - 1 mg per Tab 1 mg Inj 400 mcg per, 1 Cap 10 mg Cap 5 mg Inj 100 mg per, 2 vial Inj 50 mg per, 2 vial Eye drops 50 mcg per timolol 0.5% Inj 1%, 2 Inj 2%, 2 Mebendazole Mebendazole Mefenamic acid Metformin Methadone Methadone Minocycline Minocycline Mirtazapine Mitozantrone Mitozantrone Mitozantrone Mometasone furoate Mometasone furoate Nitazoxanide Nitrofurantoin Norethisterone Oestradiol Oestradiol Oestradiol Oestradiol Oxycodone Paracetamol Paracetamol Phenoxymethylpenic illin (Penicillin V) Phenoxymethylpenic illin (Penicillin V) Promethazine Risperidone Risperidone Oral liq 100 mg per 5 Tab 100 mg Cap 250 mg Tab immediate-release 1 g Oral liq 2 mg per Tab mg Cap 100 mg Tab 50 mg Tab 15 mg Inj 2 mg per, 10 Inj 2 mg per, 12.5 Inj 2 mg per, 5 Lotn 0.1% (pack size 30 or less) Lotn 0.1% (pack size greater than 30 ) Oral liquid 100mg per 5 Tab modified release 50 mg Tab 5 mg TDDS 100 mcg per day TDDS 25 mcg per day TDDS 50 mcg per day TDDS 75 mcg per day Tab controlled-release 5 mg Suppos 125 mg Suppos 250 mg Cap 250 mg Cap 500 mg Inj 25 mg per, 2 Orally-disintegrating tablets 0.5 mg Orally-disintegrating Page 2 of 9

3 Risperidone Sildenafil access] Sildenafil access] [current [current Sildenafil [current access] Sodium Cromoglycate Spiramycin Tobramycin tablets 1 mg Orally-disintegrating tablets 2 mg Tab 100 mg Tab 25 mg Tab 50 mg Eye drops 2% Tab 500 mg Inj 40 mg per, 2 Tobramycin Tranexamic Acid Travoprost timolol Ziprasidone Ziprasidone Ziprasidone Ziprasidone Powder BP Inj 100 mg per, 5-10 Eye drops 0.004% timolol 0.5% Cap 20 mg Cap 40 mg Cap 60 mg Cap 80 mg The following items that were included in consultation have been removed from the 2014/15 ITT: Acetylcysteine Acetylcysteine Benzoyl peroxide Soln 2.5% Benzoyl peroxide Soln 5% Cabergoline Tab 0.5 mg Inj 200 mg per, 10 Inj 200 mg per, 30 Soln 4% Soln 5% Crm 0.1% cetrimide cetrimide 0.5% cetrimide Foaming soln 0.5% cetrimide 0.5% Soln 0.5% 70%, non-staining (pink) 100 Soln 0.5% 70%, non-staining (pink) 25 Soln 0.5% 70%, non-staining (pink) 500 Soln 0.5% 70%, staining (red) 100 Soln 0.5% 70%, staining (red) 500 Soln 2% 70%, non-staining (pink) 100 Colecalciferol Colecalciferol Colecalciferol Docusate Sodium Sennosides Entecavir Soln 2% 70%, staining (red) 100 Soln 2% 70%, staining (red) 500 Oral liquid (400 1,000 iu per ) Tab (1,000 iu) Tab 1.25 mg (50,000 iu) Inj 10,000 iu per, 1 Inj 12,500 iu per, 0.5 Inj 15,000 iu per, 0.6 Inj 18,000 iu per, 0.72 Inj 2,500 iu per, 0.2 Inj 5,000 iu per, 0.2 Inj 7,500 iu per, 0.75 Tab 50 mg total sennosides 8 mg Tab 0.5 mg Crm 0.1% (pack size 30 g or less) Page 3 of 9

4 Indinavir Indinavir Iodine Isopropyl alcohol Ketoconazole Lincomycin Magnesium Methadone Crm 0.1% (pack size greater than 30 g) Milky Emulsion 0.1% (pack size greater than 30 g) Oint 0.1% (pack size greater than 30 g) Scalp lotn 0.1% Cap 200 mg Cap 400 mg Soln 70%, 100 Soln 70%, 500 Tab 200 mg Inj 300 mg per, 2 Tab Oral liq 1 mg - 2 mg per Pegfilgrastim Inj 6 mg per 0.6 prefilled syringe Povidone Iodine Oint 10% Povidone Iodine Pad 10% Povidone Iodine Soln 10% Povidone Iodine Soln 5% Povidone Iodine Soln 7.5% Povidone Iodine Swab set 10% Povidone Iodine Soln 10% 30% Povidone Iodine Soln 10% 70% Prednisolone Pregabalin Oral liq 5 mg per Cap 150 mg Pregabalin Pregabalin Pregabalin Rocuronium bromide Roxithromycin Roxithromycin Sodium hyaluronate Sodium hyaluronate Sodium Hypochlorite Solifenacin succinate Solifenacin succinate Sunitinib Sunitinib Sunitinib Terbinafine Cap 25 mg Cap 300 mg Cap 75 mg Inj 10 mg per, 5 Tab 150 mg Tab 300 mg DEHP-free IV infusion bag, 3,000 Latex-free IV infusion bag, 3,000 PVC-free IV infusion bag, 3,000 PVC-free, DEHP-free and latex-free IV infusion bag 3,000 Ophthalmic inj 14 mg per Ophthalmic soln 10 mg per Soln Tab 10 mg Tab 5 mg Cap 12.5 mg Cap 25 mg Cap 50 mg Inj 40 mg The following items have been amended in the 2014/15 ITT: Acetic acid propyelene glycol Acetylcysteine Ambrisentan Ambrisentan Amoxicillin clavulanate Ear drops 2.3% propylene glycol 2.8% Inj 200 mg per Tab 10 mg Tab 5 mg Grans for oral liq amoxycillin 125 mg potassium clavulanate Amoxicillin clavulanate Amoxicillin clavulanate Amoxicillin clavulanate mg per 5 Grans for oral liq amoxycillin 250 mg potassium clavulanate 62.5 mg per 5 Inj 1.2 g Inj 600 mg Page 4 of 9

5 Baclofen Betamethasone valerate fusidic acid Inj 0.05 mg per, 1 Crm 0.1% fusidic acid 2% Bimatoprost Eye Drops 0.03% Bortezomib Inj 1 mg Bortezomib Bosentan Bosentan Brimonidine Tartrate Timolol Maleate Cabergoline Cabergoline Calcipotriol Cefoxitin Sodium Cetomacrogol gluconate Defibrotide Desferrioxamine Mesylate Dexamphetamine Sulphate Dimethicone Erlotinib Erlotinib Inj 3.5 mg Tab 125 mg Tab 62.5 mg Eye drops 0.2% timolol maleate 0.5% Tab 0.5 mg (2 pack) Tab 0.5 mg (8 pack) Oint 50 mcg per g (pack size 30 g or less) Inj 1 g Crm BP [100 g or less] Crm 1% obstetric 51 mm or less (nominal width) 52 mm - 54 mm (nominal width) 55 mm - 58 mm (nominal width) 59 mm or greater (nominal width) Female condom Flavoured 54 mm or less (nominal width) Flavoured 55 mm or greater (nominal width) Latex-free 54 mm or less (nominal width) Latex-free 55 mm or greater (nominal width) Inj 200 mg Inj 500 mg Tab 5 mg Crm 10-15% BPC Tab 100 mg Tab 150 mg Fludarabine phosphate Miconazole paraffin and wool fat paraffin and wool fat paraffin and wool fat Hydrogen peroxide Irinotecan Irinotecan Isotretinoin Isotretinoin Latanoprost Medical lubricated jelly Miconazole Mixed salt solution for eye irrigation Mixed salt solution for eye irrigation Tab 10 mg Crm 1% miconazole nitrate 2% Lotn 1%, 100 g Lotn 1%, 15 g Lotn 1%, 500 g Soln (10 vol) Inj 20 mg per, 2 Inj 20 mg per, 5 Cap 10 mg Cap 20 mg Eye drops 50 mcg per Inj 1%, 20 Inj 1%, 5 Inj 2%, 20 Inj 2%, 5 <200 Oral gel 20 mg per g Eye irrigation solution calcium chloride 0.048% magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium acetate 0.17%, 15 Eye irrigation solution calcium chloride 0.048% magnesium chloride 0.03%, potassium chloride Page 5 of 9

6 Mixed salt solution for eye irrigation Oestriol Potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium acetate 0.17%, 250 Eye irrigation solution calcium chloride 0.048% magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium acetate 0.17%, 500 Crm 1 mg per g applicator Tab eff 548 mg (14 mmol) chloride 285 mg (8 mmol) DEHP-free IV infusion bag, 1,000 DEHP-free IV infusion bag, 250 DEHP-free IV infusion bag, 500 Latex-free IV infusion bag, 1,000 Latex-free IV infusion bag, 250 Latex-free IV infusion bag, 500 PVC-free IV infusion bag, 1,000 PVC-free IV infusion bag, 250 Sodium polystyrene sulphonate Sulphadiazine Tenoxicam Terlipressin acetate Tobramycin Topotecan Topotecan Trimethoprim sulphamethoxazole [Co-trimoxazole] Trimethoprim sulphamethoxazole [Co-trimoxazole] Zopiclone Zopiclone PVC-free IV infusion bag, 500 PVC-free, DEHP-free and latex-free IV infusion bag, 1,000 PVC-free, DEHP-free and latex-free IV infusion bag, 250 PVC-free, DEHP-free and latex-free IV infusion bag, 500 Powder Tab 500 mg Inj 20 mg Inj 1 mg Inj 100 mg per, 5 vial Inj 1 mg Inj 4 mg Inj 16 mg sulphamethoxazole 80 mg per, 5 ampoule Tab trimethoprim 80 mg and sulphamethoxazole 400 mg Tab 7.5 mg (pack size greater than 30 tablets) Tab 7.5 mg (pack size of 30 tablets or less) 2. Changes to the ITT document to incorporate Medical Devices We are proposing to make several changes to the 2014/15 ITT, as outlined below and as specifically highlighted in the Appendix to this Notification. Page 6 of 9

7 various amendments to the 2014/15 ITT document to incorporate medical devices in addition to chemical entities. inclusion of IV infusion in the 2014/15 ITT, refer to Schedule 2, paragraph 1.15 and Schedule 6, Clause 12 of the 2014/15 ITT document. alternative and varied invoicing arrangements, refer to Schedule 6, Clause 4.1 (f) of the 2014/15 ITT document. 3. Appropriate pack-size and packaging type Where possible, PHARMAC has identified Tender Items where there is a specific preference for a pack size or packaging type in Schedule Two of the 2014/15 ITT document. For example (highlighted in red): While PHARMAC has taken all reasonable care in identifying these preferences, it makes no representation as to the accuracy of this information and accepts no liability for any errors or omissions. Suppliers should always undertake their own due diligence before submitting any tender bids. 4. Oncology injectables DHBs are increasingly delivering chemotherapy treatment in satellite centers which require compounded products to have a shelf-life greater than 24 hours to account for delays in treatment transport and delivery. Due to this PHARMAC has indicated a preference for products where stability data post-compounding is greater than 48 hours in Schedule Two of the 2014/15 ITT document (highlighted in red). 5. Ophthalmology Products (BAK-free) For an number of Ophthalmology products, as indicated in Schedule Two of the 2014/15 Invitation to Tender document, PHARMAC reserves its right to list a benzalkonium chloride (BAK) or preservative-free product for a restricted market. However, where a tender product is BAK-free it would have the entire market. 6. Ambrisentan and bosentan Page 7 of 9

8 Due to the nature of these chemicals, longer transition times may apply to ambrisentan 5 mg and 10 mg tablets, and bosentan 62.5 mg and 125 mg tablets. 7. Information that must be supplied about the Tender Item. Schedule 3, Clause 3.3 of the ITT 2014/15 document has been updated to incorporate Medical Devices in the tender. Suppliers should ensure that all information set out in Schedule 3, Clause 3.3 (b)(i-viii) is provided as an attachment when submitting bids for Medical Devices. 8. Data estimates provided during consultation on the 2014/15 ITT The following annual usage data was requested by suppliers during the consultation period. The information is approximate and indicative only. PHARMAC makes no representation as to the accuracy of this information or as to the level of sales or likely sales and, while PHARMAC has taken all reasonable care in preparing the information set out below, it accepts no liability for any errors or omissions in the information. In order to be fair to all suppliers, we are unlikely to provide any further data relating to tender items while the 2014/15 ITT remains open. DHB hospital usage (1 July 2013 to 30 June 2014) Chemical name and line item Atropine sulphate Inj 600 mcg, 1 Baclofen Inj 0.05 mg per, 1 Baclofen Inj 2 mg per, 5 Bupivacaine Inj 0.25%, 20 Bupivacaine Inj 0.5%, 10 Bupivacaine Inj 0.5%, 20 sterile pack Cyclizine lactate Inj 50 mg per, 1 Flumazenil Inj 0.1 mg per, 5 Gentamicin sulphate Inj 40 mg per, 2 [lignocaine] Inj 1%, 2 [lignocaine] Inj 1%, 5 [lignocaine] Inj 1%, 20 [lignocaine] Inj 2%, 2 [lignocaine] Inj 2%, 5 [lignocaine] Inj 2%, 20 Midazolam Inj 1 mg per, 5 Midazolam Inj 5 mg per, 3 Tranexamic acid Inj 100 mg per, 5 10 DHB hospital usage 75,000 injections 15 injections 850 injections 190,000 injections 100,000 injections 130,000 injections 100,000 injections 6,500 injections 280,000 injections 5,000 injections 670,000 injections 65,000 injections 1,600 injections 110,000 injections 16,000 injections 430,000 injections 100,000 injections 140,000 injections Usage data for PCT only injectable products (1 July 2013 to 30 June 2014) Bleomycin sulphate Bortezomib Chemical Total usage 27,000,000 IU 27,000 mg Page 8 of 9

9 Carboplatin Carmustine Cisplatin Cyclophosphamide (2 g) Doxorubicin Epirubicin Etoposide (1 mg per for ECP) Etoposide phosphate Fludarabine phosphate Idarubicin injections Irinotecan Liposomal daunorubicin Mitozantrone Oxaliplatin Pegylated liposomal doxorubicin 3,200,000 mg 38,000 mg 400,000 mg 9,100,000 mg 460,000 mg 300,000 mg 44,000 mg 1,300,000 mg 54,000 mg 35,100,000 mg 4,800 mg 1,100,000 mg Not currently listed 6,700 mg 1,100,000 mg Not currently listed Vinorelbine 80,000 mg These figures have been updated from the previous usage data provided in the 2014/15 Invitation to Tender consultation dated 5 August These volumes are approximate and indicative only. PHARMAC makes no representation as to the accuracy of these figures or as to the level of sales or likely sales of any tender item. 9. More information If you have any queries regarding the tender or require any assistance the system please contact the Tender Analysts at tender@pharmac.govt.nz. Page 9 of 9